BBC News informed that secret company emails indicate that drug producer, GlaxoSmithKline, distorted trial findings in an attempt to hide a connection between its antidepressant Aropax (paroxetine) and elevated suicide risk in adolescents.
The research carried out by the company proved that the medication tripled the risk of suicidal thoughts and behavior in depressed youngsters. In spite of the trial results, Glaxo attempted to demonstrate that the medication provided some benefits to depressed adolescents.
Glaxo explained that it "rejects any indications that it has inappropriately withheld any medication trial information," BBC News informed.
The company emails were revealed when Glaxo was asked to open its confidential internal archive after bereaved families in the United States joined together to accuse the drug producer.
In one of the emails, a public relations executive working for Glaxo stated: "Initially, we had planned to do extensive media relations surrounding this research until we viewed the findings.
"Basically, the research did not really demonstrate it was successful in treating adolescent depression, which is not something we want to reveal."
